IE 11 is not supported. For an optimal experience visit our site on another browser.

Regeneca, Inc. Announces Improved Formulation for Its Lead Product RegenErect(TM)

/ Source: GlobeNewswire

IRVINE, Calif., June 14, 2011 (GLOBE NEWSWIRE) -- Regeneca, Inc., (Pink Sheets:RGNA), has improved the formulation for its lead product RegenErectTM. RegenErect is an all-natural supplement that enhances your sexual experience with no adverse side effects. The product is GMP (Good Manufacturing Practices) compliant and pre and post production quality tested to assure identity, purity and strength in every batch.

Regeneca's CEO Matt Nicosia commented, "We are excited with the improvements RegenErect's formulation. This product has been designed to naturally enhance sexual experience with no side effects. The Company will continue to commercialize RegenErect through its Direct Response Network Marketing Model."

About Regeneca, Inc.

Regeneca, Inc. (Pink Sheets:RGNA) was formed to create and commercialize premium products that help to improve health and fight the signs and symptoms of aging for a complete life of wellness and happiness, including our natural male enhancement product - RegenErect. We do this while drawing our products from the earth in an ethical strategy that will emphasize regrowth, reforestation and recycling. This is our "Whole Earth Whole Body" approach to health. More information can be found about Regeneca, Inc. at


This press release may contain forward-looking statements, including, but not limited to, statements regarding Regeneca, Inc. and their plans, products and related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Regeneca, Inc.'s filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Regeneca undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

CONTACT: Regeneca, Inc. 1 Technology Drive, Suite C-515, Irvine, CA 92618 Investor Relations 949-281-2600 extension 7